Glycinorm-M 40 Tablet is a combination oral hypoglycemic agent containing Gliclazide 40 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The synergistic action of these two agents provides effective glycemic regulation in patients inadequately controlled by diet and exercise alone or monotherapy. Glycinorm-M 40 is particularly beneficial in patients with insulin resistance and impaired beta-cell function. It is recommended to be used alongside lifestyle modifications including diet and physical activity. The medication should be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea and diarrhea. Regular monitoring of blood glucose levels, renal function, and liver enzymes is advised during therapy to detect any adverse effects early. Contraindications include severe renal or hepatic impairment, diabetic ketoacidosis, and hypersensitivity to either component. Glycinorm-M 40 Tablet offers a balanced approach to glycemic control, improving patient compliance through combination therapy while minimizing pill burden.